References
- Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narvàez AB, et al. Immune activation set point during early HIV infection predicts subsequent CD4 + T-cell changes independent of viral load. Blood 2004;104: 942–7.
- Gresele P, Falcinelli E, Sebastiano M, Baldelli F. Endothelial and platelet function alterations in HIV- infected patients. Thromb Res 2012;129:301–8.
- Gresele P, Falcinelli E, Momi S, Francisci D, Baldelli F. Highly active antiretroviral therapy (HAART)-related mechanisms of endothelial and platelet function alterations. Rev Cardiovasc Med 2014;15(Suppl 1): S9–S20.
- Neuhuaus J, Jacobs DR; INSIGHT SMART, MESA and CARDIA Study Groups. Markers of inflammation, coagulation, and renal function in HIV-infected adults in SMART and in two large population-based studies, CARDIA and MESA. Abstract 740. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009.
- Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infections. PLoS Med 2008;5:e203.
- Ledwaba L, Tavel JA, Khabo P, Maja P, Qin J, Sangweni P, et al. Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLoS One 2012;7:e24243.
- Ross AC, Rizk N, O’Riordan MA, Dogra V, El-Bejjani D, Storer N, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009;49:1119–27.
- Jones KL, Maguire JJ, Davenport AP. Chemokine receptor CCR5: from AIDS to atherosclerosis. Br J Pharmacol 2011;162:1453–69.
- Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610–21.
- Funderburg N, Kalinowska M, Eason J, Goodrich J, Heera J, Mayer H, et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4 + cell rises in HIV-infected patients. PLoS One 2010;5:e13188.
- Romero Sànchez MC, Machmach K, Gonzalez-Serna A, Genebat M, Pulido I, Garcia Garcia M, et al. Effect of maraviroc on HIV disease progression-related biomarkers. Antimicrob Agents Chemother 2012;56: 5858–64.
- Bucciardini R, D’Ettorre G, Baroncelli S, Ceccarelli G, Parruti G, Weimer LE, et al. Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors. Int J STD AIDS 2012;23:459–63.
- Baker JV, Lundgren JD. Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J 2011;32:945–51.
- Francisci D, Giannini S, Baldelli F, Leone M, Belfiori B, Guglielmini G, et al. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS 2009; 23:589–96.
- Arberas H, Guardo AC, Bargallò ME, Maleno MJ, Calvo M, Blanco JL, et al. In vitro effects of the CCR5 inhibitor maraviroc on human T cell. J Antimicrob Chemother, 2013;68: 577–86.
- Antoniou T, Smith G, Su D, Raboud JM, Lee D, Kovacs C, et al. Immunologic effectiveness of maraviroc- and raltegravir-containing regimens (R+ M+) versus raltegravir-based regimens that do not include maraviroc (R+ M−). J Int Assoc Physicians AIDS Care 2012;11:192–7.